WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"
[Brokerage Focus] CEB International raises WUXI BIO (02269) Target Price by 68.5%. Global Biomedical financing recovery is Bullish on its valuation and performance recovery.
Jingwu Financial News | According to the Research Reports from CCB International, it is expected that the biosafety bill will most likely fail in legislation, which is Bullish for WUXI BIO (02269) to continue achieving performance growth in a relatively stable Operation environment. With the recovery of Global Biomedical financing, the bank is Bullish on the Company Valuation and performance recovery. The bank maintains a Buy rating for WUXI BIO and raises the Target Price based on DCF valuation to HKD 22.88 (previous value: HKD 13.58). The bank expects WUXI BIO's 2024E/25E/26E revenue to grow year-on-year by 7.1%/12.4%/13.9%, with adjusted Net income growing year-on-year by 0.8%/1.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
The concept of contract research organizations started positively, wuxi bio (02269) rose by 13.03%, and the U.S. Biosafety Act was not included in the 2025 Fiscal Year Defense Authorization Act.
Jinwu Financial News | The contract research organizations concept started off positively, as of the time of publication, Wuxi Bio (02269) is up 13.03%, Wuxi AppTec (02359) is up 11.72%, Pharmaron (03759) is up 9.14%, Genscript Bio (01548) is up 4.98%, and Tigermed (03347) is up 4.87%. In terms of news, on December 7 local time in the USA, the final agreement text of the 2025 fiscal year National Defense Authorization Act (NDAA) released by the military committees of both the House and Senate did not include the biosafety act. Morgan Stanley stated, USA
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
